Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

1. Martín, M.
2. Ruiz, A.
3. Borrego, M.R.
4. Barnadas, A.
5. González, S.
6. Calvo, L.
7. Vila, M.M.
8. Antón, A.
9. Rodríguez-Lescure, A.
10. Seguí-Palmer, M.A.
11. Muñoz-Mateu, M.
12. Ribugent, J.D.
13. López-Vega, J.M.
14. Jara, C.
15. Espinosa, E.
16. Fernández, C.M.
17. Andrés, R.
18. Ribelles, N.
19. Plazaola, A.
20. Sánchez-Rovira, P.
21. Bofill, J.S.
22. Crespo, C.
23. Carabantes, F.J.
24. Servitja, S.
25. Chacón, J.I.
26. Rodríguez, C.A.
27. Hernando, B.
28. Álvarez, I.
29. Carrasco, E.
30. Lluch, A.
31. Mostrar todos los/as autores/as +